Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Deutsche Bank AG

Key Points

• Deutsche Bank AG reduced its stake in Moderna, Inc. by 8.3%, now holding approximately 1.74 million shares worth $49.25 million.
• Institutional investors own 75.33% of Moderna's stock, with notable increases in holdings from Russell Investments Group Ltd. by 81.3% and Advisory Services Network LLC by 543.1%.
• Moderna reported a revenue of $142 million in its latest quarterly earnings, surpassing analyst estimates, but still exhibited a 41.1% decline compared to the previous year.

Deutsche Bank AG lessened its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 8.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 1,737,365 shares of the company's stock after selling 156,710 shares during the period. Deutsche Bank AG owned about 0.45% of Moderna worth $49,254,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its holdings in shares of Moderna by 81.3% in the fourth quarter. Russell Investments Group Ltd. now owns 170,243 shares of the company's stock valued at $7,019,000 after purchasing an additional 76,350 shares in the last quarter. Advisory Services Network LLC grew its stake in shares of Moderna by 543.1% in the fourth quarter. Advisory Services Network LLC now owns 19,603 shares of the company's stock worth $815,000 after acquiring an additional 16,555 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Moderna in the fourth quarter worth $8,493,000. Treasurer of the State of North Carolina grew its stake in shares of Moderna by 3.8% in the fourth quarter. Treasurer of the State of North Carolina now owns 206,884 shares of the company's stock worth $8,602,000 after acquiring an additional 7,490 shares in the last quarter. Finally, Townsquare Capital LLC grew its stake in Moderna by 14.2% during the 4th quarter. Townsquare Capital LLC now owns 6,040 shares of the company's stock worth $251,000 after purchasing an additional 752 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Evercore ISI set a $32.00 price objective on Moderna in a research report on Friday, August 1st. Bank of America lowered their target price on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a report on Tuesday, July 22nd. Cowen started coverage on shares of Moderna in a research note on Sunday, July 13th. They issued a "hold" rating for the company. Citigroup started coverage on Moderna in a research report on Friday, August 1st. They issued a "neutral" rating and a $40.00 target price for the company. Finally, Morgan Stanley reissued an "equal weight" rating and issued a $32.00 target price on shares of Moderna in a research report on Friday, August 1st. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $43.59.

Moderna Stock Performance

MRNA stock opened at $25.47 on Tuesday. Moderna, Inc. has a one year low of $23.15 and a one year high of $91.99. The company has a fifty day moving average of $29.23 and a 200-day moving average of $29.77. The stock has a market capitalization of $9.91 billion, a PE ratio of -3.38 and a beta of 1.83.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. During the same period in the previous year, the business posted ($3.33) earnings per share. The business's revenue was down 41.1% compared to the same quarter last year. Equities analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.